Orlistat Placebo

DRUG3 trials

Sponsors

Shionogi, University of Texas Southwestern Medical Center, Shanghai 10th People's Hospital

Conditions

ObesityType 1 HyperlipoproteinemiaUric Acid

Phase 2

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

CompletedNCT01126970

ShionogiObesity

Start: 2010-04-30End: 2011-02-28Updated: 2018-05-09

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

TerminatedNCT01675154

University of Texas Southwestern Medical CenterType 1 Hyperlipoproteinemia

Start: 2015-11-30End: 2020-06-30Updated: 2021-08-19

Phase 4

Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

CompletedNCT05496075

Shanghai 10th People's HospitalUric Acid

Start: 2022-08-26End: 2023-12-01Updated: 2023-12-14

Related Papers

Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial.

2024-03-115 citations